ArticleCureus2026
The Effect of Digoxin on Mortality and Morbidity in Patients With Chronic Heart Failure: A Secondary Survival Analysis of the Digitalis Investigation Group (DIG) Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The long-term efficacy and safety of cardiac glycosides in the treatment of chronic heart failure with normal sinus rhythm remain topics of clinical debate. This study assessed the impact of digoxin on overall mortality and hospitalization rates in patients with heart failure and reduced ejection fraction. This is a retrospective secondary survival analysis of the multi-center Digitalis Investigation Group (DIG) trial dataset, undertaken to clarify digoxin's effect on mortality and hospitalizations for worsening heart failure over a 37‑month follow-up period. Methods A survival analysis was conducted using the Digitalis Investigation Group (DIG) trial dataset. Patients with a left ventricular ejection fraction of 0.45 or less were randomly assigned to receive either digoxin (n=3,397) or placebo (n=3,403). Digoxin was administered at an average dose of 0.25 mg per day over a 37-month follow-up period. Kaplan-Meier survival curves and log-rank tests were used to evaluate time-to-event outcomes, and Cox proportional hazards regression was applied to derive risk ratios and 95% confidence intervals for mortality and hospitalization endpoints. Results Digoxin therapy demonstrated no statistically significant effect on overall mortality. Death occurred in 34.8% of the digoxin group (1,181 deaths) compared to 35.1% of the placebo group (1,194 deaths), and this difference is reported as a risk ratio (RR=0.99; 95% CI: 0.91 to 1.07; P=0.80) based on the observed event proportions in each arm. However, hospitalizations were reduced in the treatment group, with a significant reduction specifically in hospitalizations for worsening heart failure, presented as a risk ratio (RR=0.72; 95% CI: 0.66 to 0.79; P=0.001) derived from the cumulative proportions of patients hospitalized in the digoxin and placebo groups. Conclusion Digoxin did not improve overall survival but significantly reduced hospitalizations for worsening heart failure in patients with chronic heart failure and reduced ejection fraction. These findings reinforce digoxin's role as an adjunct therapy focused on morbidity reduction and symptom stabilization, rather than as a primary mortality‑reducing agent, and provide additional context for its use alongside contemporary guideline‑directed heart failure treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.